Results of an exploratory study in refractory chronic cough patients suggest that AX-8 reduces awake cough frequency

Results of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:

• AX-08 significantly reduced cough frequency during waking hours in refractory chronic cough (RCC) patients compared with baseline (no therapy) in this uncontrolled pilot study; the effect seems to be most marked over  the 4 to 8 hours after dosing period.
• This was accompanied by reductions for at least 6 hours (scoring duration) in the patient-reported outcomes of cough severity, throat irritation and urge-to-cough (UTC).

Throat irritation and persistent UTC are sensations associated with coughing in patients with RCC. They participate to the distress of RCC patients and should be improved by antitussive drugs, such as AX-8, Axalbion’s lead compound.

See the results on EU Clinical Trials Register.